Home    About NDEI   Site Map   FAQ   Contact Us   Feedback   
       Advanced Search    
Home
Slide Library
Literature Alerts
On Demand Activities
Case Studies
Newsletters
Live Events
Treatment Guidelines
Patient Education
Clinical Trials
Product Indications
Calendar Of Events
Glossary
Other Resources
CME Opportunities


Your Online Resource for Diabetes Treatment
Home > Literature Alerts > Even in the Range of Nondiabetic Fasting...
Printer-Friendly Format
Email this to a friend
Highlight Glossary

Even in the Range of Nondiabetic Fasting Blood Glucose Levels, There Is an Increasing Risk of CHD as the Glucose Level Increases

Researchers at the Preventive Cardiology & Rehabilitation Department of the Cleveland Clinic Foundation have concluded that there is a correlation between rising blood glucose levels and increased risk of coronary heart disease (CHD). Investigators analyzed data for the first 2,440 high-risk patients without diabetes seen in their multidisciplinary cardiology prevention clinic between January 1996 and February 2001. The study examined relationships between the level of nondiabetic blood sugar concentration, the burden of traditional and nontraditional CHD risk factors, and the risk of CHD independent of these risk factors. Among the traditional CHD risk factors considered were age, smoking, body mass index (BMI), central obesity, hypertension, and dyslipidemia. The nontraditional risk factors considered included fibrinogen, homocysteine, and lipoprotein(a) [Lp(a)].

The patients (66% of whom were male) had dyslipidemia and/or hypertension and a fasting glucose concentration <125 mg/dL (mean 89 ± 13 mg/dL; range 37 to 125 mg/dL) and had been referred to the clinic for primary and secondary CHD prevention.

Fasting glucose quintiles were =79, 80â??86, 87â??92, 93â??99, and 100â??125 mg/dL. Increasing glucose quintiles were found to correlate directly with age (r=0.16), BMI (r=0.13), systolic BP (r=0.15), HDL cholesterol (r=-0.14), Framingham global risk score (r=0.16), fibrinogen (r=0.13), and homocysteine (r=0.08), and inversely with smoking (r=0.05) and Lp(a) (r=-0.07). P values ranged from 0.02 to <0.001.

The prevalence of CHD â?? defined on the basis of a documented myocardial infarction, >50% stenosis of =1 major coronary arteries, history of CABG, angioplasty, or stent, and/or CHD demonstrated by stress echocardiography, stress thallium scanning, or positron emission testing â?? increased progressively for both sexes with increasing blood glucose quintile (P>0.001), ranging in the whole group from 43% in the lowest quintile to 65% in the highest quintile. The odds ratio (highest to lowest quintile) for CHD was 2.5.

After adjusting for Framingham risk score (an algorithm of known CHD risk factors used to calculate the odds of developing the disease) and BMI alone, or for Framingham risk score, BMI, fibrinogen, Lp(a), and homocysteine, patients in the highest three quintiles of blood glucose continued to have a statistically significant increased likelihood of CHD. Adjustments for CHD related medications (e.g. aspirin, statins, etc.) did not diminish the relative risks ascribed to glucose.

Investigators concluded that there is a continuous relation between glucose level and CHD risk across the range of nondiabetic glucose levels, independent of traditional and nontraditional risk factors, and that this relationship is similar for men and women.

Hoogwerf BJ, Sprecher DL, Pearce GL, et al. Blood Glucose Concentrations =125 mg/dl and Coronary Heart Disease Risk. Am J Cardiol. 2002;89:596-599.

The above summary is adapted from the cited reference.



 Additional Information   Additional Information
ArticleImpaired Glucose Levels Are a Predictor of Mortality in Nondiabetic Patients With Ischemic Heart Disease, Study Finds

ArticleInsulin Resistance and Cardiovascular Events With Low HDL Cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT)

ArticleSecondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose. Results from the LIPID trial

ArticleThe Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality. The Framingham Heart Study

 

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.
Disclaimer Statement - Privacy Statement